One of the pharmaceutical stocks to have emerged as a significant gainer in recent weeks is that of Sunshine Biopharma (OTCMKTS:SBFM).
In the past week, the stock has gone up by more than 100%, and this past week, the stock got another boost after the company provided an update with regards to the working mechanism of its product Adva-27a. It is the company’s anti-cancer candidate. Sunshine revealed that the product can not only evade P-glycoprotein but also helps in inhibiting Topoisomerase II.
The first announcement is particularly vital since P-glycoprotein in cancer cells are primarily responsible for the resistance to treatments. Considering the fact that Adva-27a is able to evade P-glycoprotein, it gives the product an instance competitive advantage over many of its peers. Hence, it is not hard to see why there is a certain degree of optimism about the Sunshine stock at this point in time. The stock is expected to be on the radars of many investors next week as well.